Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test

Published on:

California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, which recently received validation through a peer-reviewed study published in Nature.

Already, Mammoth has its DETECTR platform under evaluation by the FDA for an Emergency Use Authorization (EUA), and partnering with GSK and its consumer healthcare division sets up Mammoth to potentially scale its development and distribution to widespread commercial and consumer availability. Mammoth and

Read more    Source: techcrunch.com

Leave a Reply